CVS Health says it's tried offering drug plans without rebates, but consumers don't want them.

New research is turning up evidence of rebates distorting the market, often leaving effective, less expensive generics off of formularies.

The company is not admitting wrongdoing or liability as part of its agreement with the Department of Justice.

By delaying development of generics, drugmakers can maintain their monopolies and keep prices high.

A first-of-its-kind study found that customers overpaid an average $7.69 on nearly a quarter of prescriptions by using their insurance instead of cash.